StocktoriaPasithea Therapeutics Corp. KTTA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
11.04
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | — | — | $486,559 | $15,062 |
| Gross profit | — | — | — | — | -$2,213 |
| Operating income | -$20.9M | -$14.2M | -$16.0M | -$12.6M | -$4.5M |
| Net income | -$20.4M | -$13.9M | -$16.0M | -$13.9M | -$2.2M |
| Operating cash flow | -$15.2M | -$13.9M | -$12.8M | -$11.9M | -$3.2M |
| Free cash flow | — | — | -$12.8M | -$12.0M | -$3.2M |
| Total assets | $60.2M | $16.1M | $26.1M | $45.2M | $53.3M |
| Total liabilities | $5.0M | $1.3M | $2.7M | $2.7M | $1.9M |
| Shareholders' equity | $55.2M | $14.8M | $23.4M | $42.5M | $51.4M |
| Ratios | |||||
| Gross margin | — | — | — | — | -14.7% |
| Operating margin | — | — | — | -2587.3% | -29925.7% |
| Net margin | — | — | — | -2864.3% | -14430.5% |
| FCF margin | — | — | — | -2466.6% | -21216.0% |
| Return on assets | -33.9% | -86.6% | -61.1% | -30.8% | -4.1% |
| Return on equity | -37.0% | -94.1% | -68.2% | -32.8% | -4.2% |
| Current ratio | 11.35 | 6.58 | 6.34 | 18.15 | 119.17 |
| Revenue growth | — | — | — | 3130.4% | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 93,399 | $69,283 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 11.04 (safe)
- Working capital / assets 0.855
- Retained earnings / assets -1.162
- EBIT / assets -0.346
- Equity / liabilities 10.998
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001841330 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.